Latest Breaking News On - Immunomodulation portfolio - Page 1 : comparemela.com

Synlogic Reports First Quarter Financial Results and Provides Business Update - Proof of concept studies for co-lead metabolic programs SYNB1618 in PKU and SYNB8802 in Enteric Hyperoxaluria on track for 2H 2021 readouts - - $94.4 million in cash, cash equivalents, and short-term investments as of March 31 plus April financing of $32.6 million (net) enables runway extension to 2H 2023 - - Management to host conference call and webcast at 8:30 a.m. ET today - News provided by Share this article Share this article CAMBRIDGE, Mass., May 13, 2021 /PRNewswire/  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported financial results for the first quarter ended March 31, 2021, and provided an update on its clinical and preclinical programs.

United kingdomUnited statesAoife brennanDepartment of defense doResearch laboratoryAmerican association of cancer researchSynlogic incVoigt labAmerican college of medical geneticsSynthetic bioticChief executiveEnteric hyperoxaluriaMetabolic portfolioAmerican collegeMedical geneticsImmunomodulation portfolio